The Singapore family physician最新文献_第9页

Influenza Burden and its implications in 2020 2020年流感负担及其影响

The Singapore family physician Pub Date : 2021-03-01 DOI: 10.33591/sfp.47.4.uo1

S. Y. Wong, M. Lam

引用次数: 0

Current Challenges in Osteoporosis Treatment Discontinuation 骨质疏松症停药的当前挑战

The Singapore family physician Pub Date : 2021-03-01 DOI: 10.33591/sfp.47.3.u3

A. Ching

{"title":"Current Challenges in Osteoporosis Treatment Discontinuation","authors":"A. Ching","doi":"10.33591/sfp.47.3.u3","DOIUrl":"https://doi.org/10.33591/sfp.47.3.u3","url":null,"abstract":"Osteoporosis is a chronic disease that may require lifelong therapy. Therefore, evidence-based approach regarding the efficacy and safety of long‐term osteoporosis therapy and therapy discontinuation is important. The most important goals for osteoporosis and fragility fracture patients are the recovery of pre-fracture functional level and reduction of fracture risk. There has been increasing consensus that a treat-to-target (T2T) strategy is applicable to osteoporosis and that bone mineral density (BMD) is currently the most clinically appropriate target. However, there is no clear consensus with regard to the definition of a specific BMD treatment target and timeframes applicable to T2T in osteoporosis, and these would need to be individually determined. Treatment with bisphosphonates may be interrupted after 3-5 years, only in patients in whom fracture risk is low or lowered because of the treatment itself. It is recommended never to discontinue treatment in patients with one or more prevalent osteoporotic fractures or in whom the BMD values are still below -2.5 (T score). Recent reports imply that denosumab discontinuation may lead to an increased risk of multiple vertebral fractures. Patients considered at high fracture risk should either continue denosumab therapy for up to ten years or be switched to an alternative treatment. For patients at low-risk, a decision to discontinue denosumab could be made after five years, but bisphosphonate therapy should be considered to reduce or prevent the rebound increase in bone turnover.","PeriodicalId":85774,"journal":{"name":"The Singapore family physician","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46915351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osteoporosis: A Growing Primary Care Concern 骨质疏松症：日益引起的初级保健关注

The Singapore family physician Pub Date : 2021-03-01 DOI: 10.33591/sfp.47.3.e

B. Xu

引用次数: 0

The AsthmaID Tool in Singapore: Four Simple Questions to Detect Patients in need of an Asthma Review by a Specialist 新加坡的哮喘识别工具：四个简单的问题来检测需要专家进行哮喘检查的患者

The Singapore family physician Pub Date : 2021-01-01 DOI: 10.33591/sfp.47.1.uo1

引用次数: 3

Proteinuria and Hypertension with and without Type 2 Diabetes Mellitus: 2021 Update 蛋白尿和高血压伴和不伴2型糖尿病：2021年更新

The Singapore family physician Pub Date : 2021-01-01 DOI: 10.33591/sfp.47.1.u1

AProf Goh Lee Gan

{"title":"Proteinuria and Hypertension with and without Type 2 Diabetes Mellitus: 2021 Update","authors":"AProf Goh Lee Gan","doi":"10.33591/sfp.47.1.u1","DOIUrl":"https://doi.org/10.33591/sfp.47.1.u1","url":null,"abstract":"INTRODUCTION. This 2021 paper is an update of the 2019 version. In this current update, two new items of information added. Firstly, the 2020 Consensus statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on HPDM, provided recommendations on additional medications to be considered in uncontrolled morning or night blood pressure (BP) are noted.9 Secondly, the nephroprotective properties of the SGLT-2 inhibitors are highlighted.19 Similar to the content of the 2019 version, four related areas are reviewed. They are (1) BP definition and classification; (2) Hypertension diagnosis; (3) Hypertension and proteinuria in non-diabetic patients; and (4) Proteinuria and hypertension in the patient with diabetes. METHODOLOGY. PubMed searches were done for papers to the above four topics published in the last five years (2014 to 2019). These were supplemented by papers from hand searches. RESULTS. For diagnosis of hypertension, the current cut off of 140/90 mmHg can be reduced to 130/80 to improve cardiovascular outcomes and all-cause mortality. Diagnosis of hypertension should not be based on office BP readings alone. Hypertension in older patients should be treated to prevent worse outcomes and should be individualised. In non-diabetic patients, both low grade and microalbuminuria needs to be treated; adequate BP control is needed to prevent cardiovascular outcomes and all-cause mortality. In the diabetic patient, a BP target of less than 140/90 mmHg applies to most patients, but individualisation of the BP goal is important. CONCLUSIONS. Much development in the management of proteinuria and hypertension has taken place in the last five years.","PeriodicalId":85774,"journal":{"name":"The Singapore family physician","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44146606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insulin Therapy in Type 2 Diabetes Mellitus 胰岛素治疗2型糖尿病

The Singapore family physician Pub Date : 2021-01-01 DOI: 10.33591/sfp.47.1.u2

Tan Seng Kiong, Tan Hwee Huan

引用次数: 4

Making Sense of Chronic Kidney Disease in Primary Care Part 2 – Management 在初级保健中认识慢性肾脏疾病第2部分——管理

The Singapore family physician Pub Date : 2021-01-01 DOI: 10.33591/sfp.47.1.uo4

引用次数: 0

Making Sense of Chronic Kidney Disease in Primary Care – Identification, Evaluation and Monitoring 在初级保健中认识慢性肾脏疾病——识别、评估和监测

The Singapore family physician Pub Date : 2021-01-01 DOI: 10.33591/sfp.47.1.uo3

Dr Chua Yan Ting, Clara Ngoh Lee Ying, Teo Boon Wee

引用次数: 2

Use of Continuous Glucose Monitoring (CGM) Technology in the Management of Type 2 Diabetes Mellitus in the Primary Care Setting: A Case Report 连续血糖监测（CGM）技术在初级保健环境中治疗2型糖尿病的应用：一例报告

The Singapore family physician Pub Date : 2021-01-01 DOI: 10.33591/sfp.47.1.uo2

引用次数: 0

Localising Structured Lifestyle Intervention for Dietary Management Success 本地化结构化生活方式干预促进饮食管理成功

The Singapore family physician Pub Date : 2020-09-01 DOI: 10.33591/sfp.46.7.u3

H. Singh, W. C. S. Swee

引用次数: 0